Almirall, S.A.
72
9
15
51
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
4.2%
3 terminated/withdrawn out of 72 trials
94.4%
+7.9% vs industry average
44%
32 trials in Phase 3/4
35%
18 of 51 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (72)
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
Role: collaborator
A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
Role: lead
Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
Role: collaborator
A Study of Lebrikizumab in Adults With Nummular Eczema
Role: lead
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Role: lead
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
Role: lead
A Study of LAD106 in Healthy Adult Participants
Role: lead
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
Role: lead
Study of Alloknesia in Atopic Dermatitis
Role: collaborator
A Study of LAD603 in Adults With Alopecia Areata
Role: lead
A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects
Role: lead
Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease
Role: lead
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
Role: lead
A Study of LAD191 in Adults With Hidradenitis Suppurativa
Role: lead
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Role: collaborator
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
Role: lead
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
Role: lead
Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study
Role: lead
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
Role: lead
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Role: lead